to patients with intermittent claudication, regulatory authorities, the pharmaceutical industry and healthcare providers.
Intermittent claudication, the main symptomatic expression of peripheral arterial disease (PAD), is a common condition affecting 1 to 7% of men >50 years of age, [1, 2] and represents an important cause of healthcare expenditure. [3] [4] [5] It is associated with high risk of cardiovascular mortality [6] and is responsible for a limitation in walking capacity that may adversely affect social, leisure and occupational activities. [7] [8] [9] [10] Therefore, treatment of patients with intermittent claudication has to be directed to reduce the associated systemic risk and to improve walking capacity and physical activities of daily life. The aging of populations and the continuing advances in interventional therapies suggest that the financial burden for achieving these goals will increase over time. Given the growing downward pressure to which healthcare budgets have been subjected in most developed countries, both evaluation of socioeconomic impact of disease and analyses comparing competing interventions for costs and benefits have become essential.
The purpose of this article is to review the literature on the pharmacoeconomics of treatments for intermittent claudication and to discuss the importance of quality-of-life (QOL) measurement for evaluating treatment strategies for this condition.
Reduction of Systemic Risk
PAD, coronary artery disease (CAD) and cerebrovascular disease are all manifestations of atherosclerosis and atherothrombosis. Thus, it is not surprising that patients with intermittent claudication have a high future risk of cardiovascular morbidity [11] and mortality. [6] Therefore, a multifactorial approach of risk factor modification and antiplatelet therapy is necessary to alter the natural history of intermittent claudication.
Cardiovascular Risk Factor Modification
Despite the fact that smoking, diabetes mellitus, hypertension, hyperlipidaemia and elevated plasma homocysteine levels are highly associated with PAD, [12] [13] [14] no study shows directly that preventive treatment will reduce complications of PAD. Nevertheless, a preventive approach in patients with intermittent claudication is likely to improve overall survival, reduce myocardial infarction (MI) and stroke and, perhaps, also reduce the risk of disabling leg pain, ulcers and amputation by favouring stabilisation or regression of femoral atherosclerosis. [15] [16] [17] Because CAD and intermittent claudication commonly occur together and share risk factors, economic evaluation of preventive therapies for CAD has relevance for patients with intermittent claudication. Cost-effectiveness analysis reveals that modification of cardiovascular risk factors such as tobacco use, hypertension and hypercholesterolaemia improves clinical outcomes at acceptable cost-effectiveness ratios, [18] [19] [20] usually less than $US20 000 per year of life saved. [21] More importantly, interventions such as smoking cessation or lipid modification in high-risk groups may be cost saving, with treatment costs outweighed by financial benefits. In patients with intermittent claudication, smoking cessation slows the progression to critical ischaemia and reduces the risks of MI and death of vascular causes. [5, 22] However, a recent meta-analysis reveals that smoking cessation does not improve walking capacity. [23] Large lipid-lowering clinical trials have demonstrated a significant reduction in cardiovascular events in patients with CAD. In PAD, a metaanalysis of various hypolipidaemic interventions, including diet, probucol, cholestyramine and nicotinic acid, demonstrated a nonsignificant difference in total mortality between treatments and placebo. [24] However, in treated patients, vascular peripheral disease progression was reduced. Indeed, lipid-lowering therapy is associated with stabilisation or regression of femoral atherosclerosis. [16, 17] Simvastatin was associated with a 38% risk reduction in the development or worsening of claudication. [25] In a cost-effectiveness study of patients with intermittent claudication, the cost effectiveness of secondary prevention with statins was approximately $US40 000 (1995 values) per quality-adjusted life-year (QALY) gained which is cost effective in the current health environment. [26] Therefore, the current recommendation for patients with PAD is to achieve a serum low-density lipoprotein (LDL) cholesterol level <100 mg/dl (2.6 mmol/L ) and a serum triglyceride level <150 mg/dl (1.7 mmol/L). [27] There is conflicting evidence about the efficacy of glycaemic control in reducing the progression of PAD. [28] [29] [30] [31] With respect to hypertension, the effects of its treatment on the natural history of intermittent claudication have not been evaluated. However, a subanalysis of the Heart Outcomes Prevention Evaluation Study [32] indicates that ramipril, an ACE inhibitor, reduces cardiovascular risk, although this effect is beyond that expected from blood pressure lowering.
Antiplatelet Therapy
Several large clinical trials have demonstrated that, in patients with PAD, drug-induced inhibition of platelet function reduces cardiovascular morbidity and mortality and delays the progression of PAD.
Aspirin (acetylsalicylic acid) has been reported to reduce the risk of MI, stroke or death to 9.7% versus 11.8% with placebo; [33] however, the reduction was not statistically significant. In another study, low doses of aspirin resulted in a 54% reduction in the risk of peripheral arterial surgery, as compared with placebo. [34] It should be noted that higher doses of aspirin (>325mg daily) are often associated with gastrointestinal intolerance. [35] Ticlopidine reduces the risk of stroke and fatal and nonfatal MI by 29% compared with placebo [36] and may also reduce the need for vascular surgery. [37] It can, however, result in neutropenia, an adverse effect that can be fatal because of associated increased risk for serious infection. [38] Therefore, it is recommended that the blood count be checked every 2 weeks for at least the first 3 months of therapy. Another serious and often fatal adverse effect of ticlopidine is thrombotic thrombocytopenic purpura. [39] Clopidogrel, the most recently studied antiplatelet agent, has been evaluated in a very large trial (CAPRIE study) that enrolled 19 185 individuals with cardiovascular disease, of whom 6452 had PAD. [40] In this subgroup of patients, clopidogrel (as compared with aspirin) resulted in a 23.8% relative risk reduction of ischaemic stroke, MI or vascular death. Any bleeding disorder occurred in 1.38% of patients treated with clopidogrel versus 1.55% treated with aspirin; gastrointestinal haemorrhage occurred in 0.49% of patients on clopidogrel versus 0.7% on aspirin (p < 0.05). On the basis of these data, the Cardiovascular and Renal Advisory Panel of the United States Food and Drug Administration voted that there is insufficient evidence to conclude that clopidogrel is superior to aspirin but that clopidogrel is more effective than placebo and meets all reasonable criteria for being at least equivalent to aspirin. [41] However, on the basis of the CAPRIE study, it is reasonable to conclude that, in patients with PAD, clopidogrel is superior to aspirin.
Although the efficacy of preventive therapy with aspirin is controversial, Aronow [42] suggests that aspirin should be the first-line drug for treating patients with symptomatic atherosclerosis, while the use of clopidogrel should be recommended to patients who do not respond to or who cannot tolerate aspirin. This takes into account that in 2002 the costs for a 1-month supply are $US2 to $US3 for aspirin 325mg daily, $US131.16 for ticlopidine 250mg twice daily, and $US96.22 for clopidogrel 75mg daily. Future analyses comparing the cost effectiveness of these antiplatelet therapies need to be performed in patients with intermittent claudication to determine whether significant clinical benefit may be obtained at a reasonable cost.
Improvement in Walking Capacity
The past decade has witnessed a marked increase in the evaluation and utilisation of both pharmacological and interventional therapies to treat patients with intermittent claudication. Considering that these patients have a favourable prognosis in terms of local disease, [11, 43] conservative therapy should be the primary treatment. Invasive procedures (bypass grafting, percutaneous transluminal angioplasty and stent placement) should be reserved for patients with incapacitating claudication or for the treatment of limb-threatening ischaemia, as recommended by the American Heart Association. [44] 
Exercise Rehabilitation
Exercise training elicits well established and clinically important changes in treadmill exercise performance and physical activities of daily life. [45, 46] Moreover, exercise rehabilitation has the potential to favourably modify cardiovascular risk factors. [47] Therefore, it is considered the most appropriate initial approach to relieve the disability of intermittent claudication. However, exercise rehabilitation is effective primarily when performed in a supervised programme. In one study, [48] patients with intermittent claudication were randomised to a 3-month programme of supervised exercise or home-based exercise. Patients exercising at home received detailed instructions about the rehabilitation programme and were contacted weekly by phone to assess compliance and provide encouragement. Results showed that supervised patients had improvement in quality of life, measured by both the Medical Outcomes Study 20-item Short Form health survey and the Walking Impairment Questionnaire, and an increase in peak walking time (by 137%). Conversely, those trained at home realised no benefit, showing an improvement in walking time of less than 40%.
Exercise sessions are typically held three times a week for approximately 1 hour each, and a 3-to 6-month period of training is customary. This implies expenses for transportation and, in nonretired patients, lost productivity (because of absence from work) with a consequent increase in tangible non-healthcare costs. As a result, patient acceptance of and compliance with exercise training is an important issue. Many patients may have contraindications for exercise (e.g. severe CAD, musculoskeletal limitations or neurological impairment); other patients may be unwilling to participate in supervised sessions if they have long distances to travel. [49] The question as to whether exercise is superior to angioplasty is controversial, with some authors reporting that patients randomised to exercise benefited more than those receiving angioplasty and others reporting opposite results. [50] [51] [52] Lundgren et al. [53] compared the effects of peripheral bypass surgery alone, surgery followed by supervised exercise training, and supervised exercise training alone. At 13 months after randomisation, walking capacity increased more in surgically treated patients than in those who received exercise training alone. The latter group, however, had a lower rate of complications than the group undergoing surgery.
Unfortunately, to date, no cost analysis of exercise training has been performed. Future studies will need to address the cost benefit of exercise as compared with other treatments.
Pharmacological Therapy
At present, no pharmacological agent has been proven to be efficacious enough to gain widespread acceptance and use for improving walking capacity. However, recent pharmacological advances have led to a greater use of drugs to treat intermittent claudication, with new agents in clinical development. [54] Pentoxifylline, which improves blood rheology, has been the most extensively evaluated and most widely used drug for intermittent claudication. Its efficacy has been tested in many placebo-controlled, blinded clinical trials, the results of which are controversial. [23, [55] [56] [57] [58] [59] [60] In particular, Cameron et al. [58] reviewed the results of placebo-controlled trials with pentoxifylline and found a negative correlation between sample size and outcome. This may be due to the fact that investigators may tend to withhold publication of negative results from small studies, but positive results are published. Conversely, findings from large studies tend to be published even with negative or less favourable results. The overall clinical utility of pentoxifylline is also limited by drug intolerance, costs of therapy [61] and inconsistent clinical response. [61, 62] Cilostazol is a phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator. [63] However, vasodilators and antiplatelet drugs do not increase walking capacity in patients with intermittent claudication, and thus the mechanism of the effect of cilostazol in intermittent claudication is unknown. Compared with placebo, cilostazol 100 or 50mg twice daily significantly improves treadmill walking capacity and several aspects of physical functioning and quality of life. [60, 64, 65] Additional properties of the drug include a modest decrease in triglycerides and LDL-and total cholesterol levels and an increase in high-density lipoprotein cholesterol levels. [64] [65] [66] Type 3 phosphodiesterase inhibitors, such as milrinone, have been previously developed as inotropic agents for treating heart failure, and their use has been associated with an increase in mortality. [67] Compared with milrinone, cilostazol has less cardiac inotropic effect but equivalent vasodilating and platelet-inhibiting properties. [68] Available data indicate that cilostazol is a well tolerated drug, headache and gastrointestinal effects being the most commonly reported adverse events.
Propionyl-L-carnitine, an ester of L-carnitine, stimulates energy production in ischaemic muscles by increasing the flux in the Krebs cycle and stimulating pyruvate dehydrogenase activity. [69] Furthermore, it may act as a free radical scavenger. [70, 71] Three large trials demonstrated that propionyl-Lcarnitine at a dosage of 2 g/day is effective in improving walking capacity and quality of life in patients with intermittent claudication. [72] [73] [74] [75] Interestingly, in terms of cost effectiveness, these beneficial effects were achieved in patients who walked a treadmill distance <250m before randomisation, while no difference between propionyl-Lcarnitine and placebo was observed in those with a maximal walking distance >250m. [74] This finding is consistent with the previous observation that only the most affected patients with intermittent claudication require carnitine supplementation, because they, and not those with mild functional impairment, have reduced availability of endogenous carnitine to meet the increased metabolic demand induced by walking. [76] Propionyl-L-carnitine is safe and well tolerated. In the European multicentre trial [74] the incidence of adverse events was 29% in the propionyl-L-carnitine group and 54% in the placebo group. Influenza syndrome was the most frequent effect in both groups.
Recently, the efficacy and safety of beraprost, a new stable, orally active prostaglandin I2, has been evaluated in 422 patients with intermittent claudication. [77] With respect to the main outcome of the study (i.e. improvement of >50% in pain-free walking distance at 6 months in the absence of critical cardiovascular events), there were 43.5% of responders in the beraprost group and 33.3% in the placebo group (p = 0.036). At the end of the treatment, an improvement of >50% in pain-free walking distance was observed in 56.5% of patients on beraprost and 42.2% of patients on placebo. The incidence of critical cardiovascular events was 4.8% in the beraprost group and 8.9% in the placebo group (p = 0.092). The number of arterial thromboses of the leg was surprisingly high (eight on beraprost, 14 on placebo), as compared with that in other claudication studies.
Naftidrofuryl is a serotonin 5-HT 2 receptor antagonist that also exerts beneficial effects on oxidative metabolism and on blood rheology. A retrospective data analysis of five randomised, controlled studies concluded that naftidrofuryl improves initial but not maximal walking distance. [78] Efficacy and safety analyses, by evaluating risks and benefits of a treatment, contribute to healthcare decisions; these decisions, however, also involve comparison of the costs and consequences of different treatments (through costeffectiveness, cost-utility and cost-benefit studies). Unfortunately, as previously reported, [79] there are few published economic evaluations of drugs for intermittent claudication. In one study, [80] the use of a therapeutic dose of pentoxifylline for 120 days significantly reduced the require-ment for invasive therapy and diagnostic procedures related to PAD. However, in a more recent retrospective study, Zachry et al. [81] observed that aspirin was more effective than pentoxifylline in reducing PAD-related invasive procedures. Another study [82] reviewed controlled clinical trials for intermittent claudication and reported the ambulatory costs of drug treatment, which had been shown to improve the pain-free walking distance by at least 30% over placebo or absence of treatment. Costs included the purchase of the drug and physician fees in 1994. The duration of treatment varied from 2 to 8 months. When considering the effects of treatment on pain-free walking distance, it appeared that supervised exercise alone had as good a result as most drugs, but at a cost of $US504 per 24 months, including physiotherapist fees.
Invasive Procedures
Revascularisation for PAD with bypass surgery, percutaneous transluminal angioplasty and stent placement is generally considered effective in treating disabling claudication. These procedures should be adopted only in patients in whom failure of the noninvasive approach has been observed or may be predicted because of the severe disability of the patient at presentation. Furthermore, the morphology and location of the atherosclerotic lesion(s) must be suitable for intervention. [44] In the US, more than 400 000 hospitalisations for PAD occur annually, including an estimated 50 000 angioplasties, 110 000 bypass operations and 69 000 foot or lower-limb amputations. [3, 4] The optimal revascularisation procedure, however, remains debatable. [83] [84] [85] [86] Hunink et al. [87] evaluated the relative benefits and cost effectiveness of revascularisation for femoropopliteal disease, using a multistate transition stimulation model (Markov process). Results revealed that angioplasty is the preferred initial treatment in patients with disabling claudication and a femoropopliteal stenosis or occlusion and in those with chronic critical ischaemia and a stenosis. Conversely, bypass surgery is the preferred initial treatment in patients with chronic critical ischaemia and a femoropopliteal occlusion. A recent study assessed the costs of angioplasty alone and angioplasty with selective stent placement and evaluated the cost effectiveness of the two procedures. [88] Results demonstrated that, from the perspective of the interventional radiology department, angioplasty with stent placement costs more than angioplasty alone ($US2926 vs $US2106). However, taking into account followup costs and procedures for long-term failures, the cost differential was reduced because of a lower failure rate of selective stent placement ($US13 158 vs $US12 458). As a consequence, angioplasty with selective stent placement is a cost-effective treatment strategy compared with angioplasty alone in the treatment of intermittent claudication.
Quality of Life
Although survival time, adverse reactions and laboratory tests offer the advantages of objective, quantified measurements, this 'hard' information does not account for many important clinical and human reactions (i.e. quality of life), which represents the primary goal of healthcare for patients with chronic conditions. Indeed, in recent years assessment of quality of life has been extensively used for measuring the impact of diseases and their treatment and for deciding priorities when allocating resources.
Two basic types of instrument are available to measure quality of life: specific instruments that focus on problems associated with individual diseases and generic instruments. The latter include health profiles that span a number of dimensions such as physical activity, social role and emotional function and thus cover the complete spectrum of function, disability and distress that is relevant for quality of life, and utility measures that are derived from economic and decision theories and reflect the preferences of patients for treatment process and outcome. These latter instruments are used for cost-utility analysis in which the cost of an intervention is related to the number of QALYs gained through application of the intervention. The two approaches for measuring quality of life are not mutually exclusive; each has its strengths and weaknesses [89] and may be suitable under different circumstances.
Specific Health Status Questionnaires
Probably, the oldest disease-specific questionnaire for intermittent claudication is the one developed by Rose et al. [90] It identifies patients with claudication, but does not allow a rating of physical function impairment. More recently, the Walking Impairment Questionnaire (WIQ) was developed to quantify the walking ability of patients with intermittent claudication in terms of defined distances and speed and to rate the severity of claudication pain during usual walking activities. [91] The WIQ was used to evaluate changes in daily-life physical activity in response to exercise training [92] and surgical interventions. [93] Changes in treadmill exercise performance correlated with changes in questionnaire scores [91] and thus the WIQ may be useful in settings where treadmill testing is impractical.
The PAD Physical Activity Recall questionnaire is a measure of habitual physical activity and provides a global estimate of the total energy expended in multiples of resting oxygen consumption (MET) hours per week by the patient at work, in the home and during leisure time. [94] 
Generic Health Status Questionnaires
Generic instruments can be divided into two major classes: health profiles and utility measures. Health profiles measure different aspects of quality of life. They share a scoring system and can be aggregated into a few scores or sometimes even one (an index). Several health profiles have been used to measure quality of life in patients with intermittent claudication (table I). Although somewhat different in format, each of these instruments demonstrated that patients with intermittent claudication have poorer scores on various measures of functional health and well-being than persons of similar age without the disease. [7] [8] [9] [10] 95] Unlike that observed for the WIQ (section 3.1), generic instruments poorly correlate with treadmill performance. [9, 96, 97] This implies that the treadmill test alone does not directly define the degree of functional disability experienced by the patient in everyday life. Therefore, the evaluation of claudication requires a comprehensive approach, using both objective exercise testing and patient-focused clinical outcomes, such as outpatient walking ability or quality of life. [98] The Transatlantic InterSociety Consensus on the management of PAD recommends the use of QOL instruments in all therapeutic trials for claudication and suggests that ultimately QOL assessment may become a primary endpoint. [99] Indeed, the success of a therapy for claudication cannot be adequately evaluated if treatment results are expressed exclusively in 'hard' data, such as treadmill performance. This is clearly documented by a recent trial with propionyl-L-carnitine. [73] Treatment effects were analysed in patients with a baseline walking capacity <250m and in those with a walking capacity >250m. These two populations experienced similar improvement in maximal walking capacity after 6 months of treatment with propionyl-L-carnitine. However, only in the most affected patients did the increase in walking capacity parallel an improvement in quality of life. These data suggest also that treatment with propionyl-Lcarnitine may be more cost effective in patients with a maximal walking capacity <250m. This is in agreement with the finding by Arfvidsson et al., [97] who reported that patients with a maximal walking capacity <70 watts have significant reduction in everyday life function as opposed to those performing a higher level of treadmill work.
Utility measures are derived from economic and decision theories and reflect the preferences of pa- McMaster Health Index Questionnaire PAD Physical Activity Recall
General Well-Being Questionnaire tients for treatment process and outcome. Quality of life is measured as a single number along a continuum and may vary from 0.0 (death) to 1.0 (full health). As reported by Guyatt et al., [89] there are two fundamental approaches to utility measures. The first approach consists of asking patients a number of questions and classifying the patient. The second approach is to ask patients to make a single rating of all aspects of their quality of life. This may be accomplished in many ways, such as the standard gamble, in which participants are asked to choose between their own health state and a gamble that they may die immediately or achieve full health for the remainder of their lives; the quality of life is determined by the choices made as the probabilities of immediate death or full health are varied. A simplified, more widely used technique is the time trade-off: participants are asked how many years in their present health state they would be willing to trade off for a shorter life span in full health. The major advantage of utility measures is their amenability to cost-utility analysis, in which the cost of an intervention is related to the number of QALYs gained. In intermittent claudication, a cost-effectiveness analysis published in 1998 showed that compared with exercise training, treatment strategies including percutaneous transluminal angioplasty or both angioplasty and reconstructive surgery improved quality-adjusted life expectancy, but the incremental cost-effectiveness ratios were very high: $US 37 000 to $US82 000 per QALY gained for angioplasty and $US202 000 to $US779 000 for QALYs gained for strategies including both angioplasty and reconstructive surgery. [100] The limits of utility measures consist of not being responsive to small yet clinically important changes and not allowing the determination of what aspects of quality of life are responsible for any changes in utility.
Choosing an Appropriate Questionnaire
A wide variety of generic QOL measures have been used for analysing the impact of intermittent claudication and its treatment on patients' subjective well-being and life satisfaction. This use of different instruments reflects the fact that a consensus has not been reached on which questionnaire is the most appropriate in this specific group of patients and makes comparison between studies and treatments difficult. Therefore, there is a need for a single, standardised instrument specifically developed for measuring quality of life in patients with intermittent claudication. This ideal instrument should include questions about problems that are relevant for patients with intermittent claudication in their daily life, and, according to Beattie et al., [101] it should be of proven validity when applied across geographic, linguistic and cultural boundaries.
CLAU-S is a disease-specific QOL scale originally developed in Germany for patients with intermittent claudication. [102] In its current format, the CLAU-S scale evaluates five dimensions: 'daily living', 'pain', 'social life', 'disease-specific anxiety' and 'mood', for a total of 47 items. The questionnaire has been translated and validated in French, English and Flemish and shows good convergence and discriminatory power. Using this scale, naftidrofuryl has been shown to significantly improve several aspects of the quality of life in patients with intermittent claudication. [103] The ARTEMIS scale, [104] developed in France, is a questionnaire composed of a general [Medical Outcomes Study 36-item Short Form health survey (SF-36)] and a specific instrument developed by the authors. It comprises 64 items covering the eight dimensions of the SF-36, five specific dimensions (physical and psychological impairment; difficulty in social life; distress as a consequence of the illness; degree of satisfaction for own health status, daily activities, and physical attitudes; and impairment in sexual function) and two differential dimensions (perception of health status evolution and perception of the future). The ARTEMIS scale was validated in 177 French patients with intermittent claudication. To our knowledge, ARTEMIS has not been translated into other languages. A large clinical trial that used this scale demonstrated that ifenprodil improved quality of life in patients with intermittent claudication. [105] We have recently developed a 22-item questionnaire (ST-22) covering the following dimensions: 'walking/pain' (effect of leg pain on the walking function), 'global physical function' (degree of limitation experienced by the patient with intermittent claudication in performing habitual physical activities), 'social function' (work/social role performance, family and friend relationships, ability to spend free time), and emotional function (extent to which patients with intermittent claudication become distressed, anxious or depressed as a consequence of their illness). The ST-22 questionnaire has been shown to be valid, sensitive to change and reliable, with a strong internal consistency. [106] It has been translated into English, German, French, Dutch, Russian, Croatian and Slovenian and adopted by the physicians of those countries who participated in the European multicentre study on the effects of propionyl-L-carnitine in intermittent claudication. [74] A study comparing these questionnaires should be carried out, and the instrument most valid, reliable and responsive to change should be recommended for widespread adoption.
Conclusions
Data on the economics of intermittent claudication are scarce and present several limitations.
Most studies did not estimate the non-healthcare costs, such as the loss of productivity at the time of intervention and the expenses for transportation and home help that have to be borne by, for example, a patient engaged in a supervised exercise training programme.
Another limitation is represented by the lack of information on the presence of concomitant cardiovascular diseases that have a great influence on costs. Furthermore, the interpretation of results is made difficult by between-country differences in healthcare and non-healthcare costs and in the general organisation of healthcare delivery. Decision analysis is a method to evaluate the trade-offs relevant to a therapeutic decision by mathematically modelling the risks, effectiveness and costs of all potential interventions. A theoretical model integrates all the available evidence and analyses which therapeutic strategy optimises management under varying assumptions. Every model has some uncertainty associated with it, which may be analysed by sensitivity analysis. each time drawing values for the uncertain variables at random from their corresponding distribution. The resulting distribution of outcomes (typically costs and effectiveness) represents the uncertainty in the results. Using such simulation experiments, it is possible to simulate a clinical trial before actually performing it, which can help focus the research question and pinpoint the information that needs to be collected during the trial. Examples of such simulation experiments exist in the area of PAD. [87, 107] Clinical trials and modelling studies complement each other. Based on the decision model, the two most relevant therapeutic strategies emerged by previous clinical trials may be subsequently compared in a randomised, controlled clinical trial in which only short-and midterm costs and health benefits are measured. The lifetime benefits and costs can then be estimated using the decision model with inputs based on the clinical trial. Although these types of studies are needed in the field of PAD, there is general agreement that, in patients with intermittent claudication, preventive strategies for reducing cardiovascular morbidity and mortality are effective. With respect to the second objective in the treatment of intermittent claudication, i.e. improvement in walking capacity, revascularisation procedures are considered to be cost effective when the intervention (transluminal angioplasty or bypass surgery) is appropriate to the morphology and location of the atherosclerotic lesion(s), and it is adopted for patients with severely disabling claudication. Patients with mild to moderate claudication and those not suitable for endovascular and surgical procedures should be considered for treatment with supervised exercise training. This approach induces clinically relevant improvements in exercise performance and community-based walking capacity. However, its application may be limited by factors such as contraindications for exercise and elevated non-healthcare costs. In one study [49] of 201 patients recommended for exercise, 34% had contraindications, and 36% of the remaining patients refused to participate.
The efficacy of pharmacological therapy remains to be proven. Many drugs have been demonstrated to induce a significant improvement in walking capacity. 'However, the evidence is mathematical. It remains the obligation for the researcher to assure that the 'significance' has biological and human importance.' [108] Therefore, the use of QOL assessment conforms to an underlying premise in health and social sciences that healthcare is provided to improve the welfare of patients. [109] This is a question of evaluating the cost/benefit of treatment, and incorporating considerations of issues such as adverse effects, potential risks and costs (figure 1). Pecuniary and QOL evaluations complement each other by adding information that is extremely useful to clinicians in their decisions concerning patient management. Furthermore, these studies also provide third-party payers, regulatory authorities and others with important information on the costs and consequences of various uses of scarce healthcare resources.
